Study guide
9.3 Cardiogenic Shock, Cardiac Tamponade & Cardiac Arrest Resuscitation
Cardiac-Vascular Nursing CV-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 ANCC CV-BC Certification Facts & Exam Overview 1.2 Clinical Reasoning & Study Strategies for Cardiac Nurses
2 Chapter 2: Cardiac Anatomy, Electrophysiology & Pathophysiology
2.1 Cardiac Anatomy, Electrophysiology & Hemodynamics 2.2 Pathophysiology of CAD, ACS & Heart Failure Syndromes 2.3 Valvular Disorders, Vascular Diseases & Aortic Pathologies
3 Chapter 3: Assessment, Diagnostic Modalities & Nursing Diagnoses
3.1 Nursing Diagnosis Identification & Clinical Decision Making 3.2 Patient Interview, Symptom Analysis & Social Determinants 3.3 Physical Examination Techniques, Heart Sounds & Bedside Tools 3.4 Diagnostic Tests, Lab Biomarkers & ECG Rhythm Analysis
4 Chapter 4: Evidence-Based Guidelines, Nursing Scope & Ethics
4.1 Evidence-Based Practice Guidelines & Quality Measures 4.2 Cardiovascular Nursing Scope & Professional Standards 4.3 Informed Consent, Advance Directives & Ethical Dilemmas
5 Chapter 5: Catheterization, Surgical Procedures & Mechanical Circulatory Support
5.1 Cardiac Catheterization, Percutaneous Interventions & Structural Heart 5.2 Coronary Bypass, Surgical Valve Repair & Vascular Revascularization 5.3 Mechanical Circulatory Support (LVAD, IABP, ECMO) & Heart Transplantation
6 Chapter 6: Cardiovascular Pharmacotherapy
6.1 Inotropes, Vasopressors & Vasoactive Infusions 6.2 Antihypertensives & Guideline-Directed Heart Failure Therapies 6.3 Antithrombotic Agents, Antiarrhythmics & Lipid Management
7 Chapter 7: Interventions, Risk Reduction & Clinical Coordination
7.1 Non-Pharmacologic Therapies, Cardiac Nutrition & Exercise 7.2 Clinical Risk Reduction, VTE Prophylaxis & Infection Prevention 7.3 Interdisciplinary Coordination, Targeted Temperature Management & Cardioversion
8 Chapter 8: Outcome Evaluation, Drug Interactions & Complication Management
8.1 Evaluating Expected Outcomes & Managing Cardiovascular Drug Interactions 8.2 Recognition and Treatment of Adverse Reactions & Clinical Complications
9 Chapter 9: Urgent & Emergent Cardiovascular Crises
9.1 Recognition and Treatment of Urgent Cardiovascular Conditions 9.2 Recognition and Immediate Management of Emergent Cardiovascular Crises 9.3 Cardiogenic Shock, Cardiac Tamponade & Cardiac Arrest Resuscitation
10 Chapter 10: Chronic Disease Management, Risk Factors & Patient Education
10.1 Cardiovascular Risk Factors, Epidemiology & Health Disparities 10.2 Long-Term Management of Chronic Cardiovascular Diseases 10.3 Essential Patient & Family Educational Topics 10.4 Self-Management Strategies, Home Monitoring & Symptom Action Plans
11 Chapter 11: Health Literacy, Cardiac Rehabilitation & Outpatient Services
11.1 Individualized Education Planning, Health Literacy & Cultural Competence 11.2 Community Resources, Cardiac Rehabilitation & Outpatient Services 11.3 Outpatient Telemetry, Remote Monitoring & Community Health Promotion
9.3 Cardiogenic Shock, Cardiac Tamponade & Cardiac Arrest Resuscitation
Key Takeaways Explain This Topic AI
Cardiogenic shock is characterized by persistent hypotension (SBP <90 mmHg or MAP <65 mmHg), severely depressed Cardiac Index (<2.2 L/min/m²), elevated pulmonary artery occlusion pressure (PAOP >15 mmHg), and systemic hypoperfusion (elevated lactate, oliguria, cool extremities), classified into SCAI stages A through E (At risk, Beginning, Classic, Deteriorating, Extremis).
Norepinephrine is the first-line vasopressor in cardiogenic shock to maintain coronary and systemic perfusion pressure with lower arrhythmogenicity than dopamine, frequently paired with inotropes (dobutamine or milrinone) and early mechanical circulatory support (IABP, Impella, or VA-ECMO).
Cardiac tamponade is marked by Beck's triad (hypotension, elevated JVP/distended neck veins, muffled heart sounds), pulsus paradoxus (>10 mmHg inspiratory drop in SBP), and electrical alternans on ECG, necessitating immediate emergent pericardiocentesis via a subxiphoid approach or surgical pericardial window.
AHA ACLS guidelines mandate high-quality CPR metrics: compression depth of 2 to 2.4 inches (5 to 6 cm), rate of 100 to 120/min, full chest recoil, minimal interruptions (chest compression fraction >60-80%), and end-tidal CO2 (PETCO2) monitoring where a sudden rise to ≥35-40 mmHg indicates return of spontaneous circulation (ROSC).
Cardiac arrest resuscitation branches into shockable rhythms (VF / pulseless VT: immediate unsynchronized biphasic defibrillation at 120-200 J, epinephrine 1 mg IV/IO every 3-5 minutes, amiodarone or lidocaine) and non-shockable rhythms (PEA / asystole: immediate CPR, early epinephrine, and systematic investigation and treatment of reversible H's and T's).
Last updated: September 2026
9.3 Cardiogenic Shock, Cardiac Tamponade & Cardiac Arrest Resuscitation
Note
ANCC Blueprint Focus : Advanced resuscitation and hemodynamic stabilization in critical cardiovascular collapse form the core of Domain III (Evaluation and Modification) and Domain II (Planning and Implementation). Registered nurses must master invasive hemodynamic profiles, stage-based cardiogenic shock management, pericardiocentesis assistance, and high-fidelity ACLS execution.
Survival in catastrophic cardiovascular collapse hinges on prompt hemodynamic classification, rapid mechanical and pharmacologic unloading, and immediate execution of high-quality cardiopulmonary resuscitation.
Cardiogenic Shock: Definition, Hemodynamics & SCAI Classification
Cardiogenic Shock (CS) is a state of critical end-organ hypoperfusion and cellular hypoxia caused by primary cardiac pump dysfunction despite adequate or elevated intravascular volume.
Invasive Hemodynamic Diagnostic Criteria
Cardiogenic shock is confirmed by invasive pulmonary artery catheterization or clinical bedside criteria:
Persistent Systemic Hypotension : Systolic Blood Pressure S B P < 90 mmHg SBP < 90\text{ mmHg} SBP < 90 mmHg or Mean Arterial Pressure M A P < 65 mmHg MAP < 65\text{ mmHg} M A P < 65 mmHg for > 30 minutes >30\text{ minutes} > 30 minutes , or the continuous requirement for vasoactive infusions to sustain perfusion.
Severely Depressed Cardiac Index : C I < 2.2 L/min/m 2 CI < 2.2\text{ L/min/m}^2 C I < 2.2 L/min/m 2 (or < 1.8 L/min/m 2 <1.8\text{ L/min/m}^2 < 1.8 L/min/m 2 without pharmacologic/mechanical support).
Elevated Ventricular Filling Pressures : Pulmonary Artery Occlusion Pressure P A O P > 15 mmHg PAOP > 15\text{ mmHg} P A OP > 15 mmHg (frequently > 18 to 22 mmHg >18\text{ to }22\text{ mmHg} > 18 to 22 mmHg ) and Central Venous Pressure C V P > 12 mmHg CVP > 12\text{ mmHg} C V P > 12 mmHg .
Systemic Tissue Hypoperfusion Markers : Serum lactate > 2.0 mmol/L >2.0\text{ mmol/L} > 2.0 mmol/L , oliguria ( < 0.5 mL/kg/hr <0.5\text{ mL/kg/hr} < 0.5 mL/kg/hr ), cool, clammy extremities, delayed capillary refill, altered mental status, and low mixed venous oxygen saturation ( S v O 2 < 60 to 65 % SvO_2 < 60\text{ to }65\% S v O 2 < 60 to 65% ).
The SCAI Shock Classification (Stages A through E)
The Society for Cardiovascular Angiography and Interventions (SCAI) established a unified staging system to guide escalation of medical and mechanical therapies:
SCAI Stage Designation Clinical & Hemodynamic Characteristics Nursing & Resuscitation Interventions
Stage A At Risk Patient is normotensive ( S B P ≥ 100 mmHg SBP \ge 100\text{ mmHg} SBP ≥ 100 mmHg , M A P ≥ 65 mmHg MAP \ge 65\text{ mmHg} M A P ≥ 65 mmHg ) with normal tissue perfusion, but has suffered an acute cardiac insult (e.g., large STEMI, acute myocarditis, decompensated cardiomyopathy). Continuous telemetry monitoring, serial cardiac biomarkers, maintain euvolemia, and optimize guideline-directed therapy.
Stage B Beginning Compensatory phase. Clinical evidence of hemodynamic instability (sinus tachycardia H R ≥ 100 bpm HR \ge 100\text{ bpm} H R ≥ 100 bpm , relative hypotension S B P < 90 mmHg SBP < 90\text{ mmHg} SBP < 90 mmHg or M A P < 65 mmHg MAP < 65\text{ mmHg} M A P < 65 mmHg ), but normal perfusion markers (lactate < 2.0 mmol/L <2.0\text{ mmol/L} < 2.0 mmol/L , normal urine output). Close ICU monitoring, cautious fluid challenge if filling pressures uncertain; prepare vasoactive medications.
Stage C Classic True cardiogenic shock . Marked hypoperfusion manifested by elevated lactate ( > 2.0 mmol/L >2.0\text{ mmol/L} > 2.0 mmol/L ), oliguria ( < 0.5 mL/kg/hr <0.5\text{ mL/kg/hr} < 0.5 mL/kg/hr ), cold/clammy skin, C I < 2.2 L/min/m 2 CI < 2.2\text{ L/min/m}^2 C I < 2.2 L/min/m 2 , and P A O P > 15 mmHg PAOP > 15\text{ mmHg} P A OP > 15 mmHg requiring initial inotrope, vasopressor, or mechanical circulatory support. Initiate first-line vasopressor (norepinephrine) and inotrope (dobutamine/milrinone); prepare for early invasive arterial line and PA catheter.
Stage D Deteriorating Failure to respond to initial inotrope/vasopressor therapy. Hypoperfusion worsens despite escalating doses; persistent lactic acidosis, oliguria, and deepening shock. Rapid escalation to temporary mechanical circulatory support (Impella, IABP, VA-ECMO); multidisciplinary shock team activation.
Stage E Extremis Catastrophic circulatory collapse. Refractory cardiac arrest with ongoing CPR, or multi-organ failure with profound metabolic acidemia ( p H < 7.20 pH < 7.20 p H < 7.20 , lactate > 8 mmol/L >8\text{ mmol/L} > 8 mmol/L ). Advanced life support, emergency VA-ECMO (E-CPR), mechanical LV venting, immediate salvage interventions.
Pharmacotherapy & Mechanical Circulatory Support in Cardiogenic Shock
Vasopressor Selection : Norepinephrine is the guideline-directed first-line vasopressor of choice. The landmark SOAP-II trial established that dopamine is associated with a significantly higher incidence of tachyarrhythmias and increased mortality in cardiogenic shock compared to norepinephrine. Norepinephrine restores coronary perfusion pressure via selective α 1 \alpha_1 α 1 vasoconstriction while providing modest β 1 \beta_1 β 1 inotropy without excessive tachycardia.
Inotropic Support : Dobutamine (2.5 to 10 mcg/kg/min; β 1 \beta_1 β 1 -dominant inotrope) or Milrinone (0.25 to 0.5 mcg/kg/min; PDE-3 inodilator). Milrinone is particularly effective in patients receiving chronic beta-blocker therapy and those with elevated pulmonary artery pressures, but requires dose reduction in renal dysfunction and may worsen hypotension. [ TEMPORARY MCS MODALITIES ]
- │
- ┌────────────────────────────────┼────────────────────────────────┐
- ▼ ▼ ▼
- Intra-Aortic Balloon Pump Impella Microaxial Flow Pump Veno-Arterial ECMO
- (IABP) (Impella CP / 5.5) (VA-ECMO)
- Counterpulsation in aorta - Microaxial pump across aortic valve - Full biventricular &
- Inflates in Diastole: Draws blood from LV -> Aorta pulmonary support
- Augments coronary perfusion - Active LV Unloading (3.5-5.5 L/min) - Draws venous blood ->
- Deflates in Pre-Systole: - Lowers PAOP, wall stress, and MVO2 Oxygenates -> Pumps into
- Reduces afterload & MVO2 - First-line for severe LV failure femoral artery
- CONTRAINDICATIONS: - CONTRAINDICATIONS: - Increases LV afterload
- Aortic Regurgitation, Mechanical aortic valve, severe AR, (requires venting with
- Aortic Dissection, severe PAD LV thrombus Impella = 'ECPELLA')
Cardiac Tamponade: Pathophysiology, Beck's Triad & Pericardiocentesis
Cardiac tamponade is an acute, life-threatening condition in which fluid accumulation in the pericardial space elevates intrapericardial pressure to equal or exceed intracardiac chamber filling pressure. This impairs diastolic ventricular filling, reduces stroke volume, and precipitates severe low-output cardiogenic collapse.
Pathophysiological Cascade: Intrapericardial Pressure & Equalization
Loss of Pericardial Compliance : The normal pericardial sac contains 15 to 50 mL of lubricating serous fluid. When fluid accumulates rapidly (e.g., hemopericardium from cardiac rupture, trauma, aortic dissection, or post-catheterization wire perforation), as little as 150 to 200 mL exceeds the elastic limit of the fibrous pericardium, causing an exponential surge in intrapericardial pressure.
Equalization of Diastolic Pressures : As intrapericardial pressure rises, it compresses the thin-walled right atrium and right ventricle during diastole. Invasive hemodynamic monitoring reveals equalization of end-diastolic pressures throughout all four cardiac chambers ( R A P ≈ R V E D P ≈ P A D ≈ P A O P RAP \approx RVEDP \approx PAD \approx PAOP R A P ≈ R V E D P ≈ P A D ≈ P A OP ).
Impaired Stroke Volume : Compression prevents diastolic expansion, causing stroke volume and cardiac output to collapse.
Clinical Presentation: Beck's Triad & Pulsus Paradoxus
Beck's Triad (The Classic Diagnostic Triad) :
Hypotension with a narrowing pulse pressure (due to severely depressed stroke volume).
Jugular Venous Distension (JVD) with prominent neck veins and loss of the normal rapid y y y -descent (elevated central venous pressure with impaired right atrial emptying).
Muffled / Distant Heart Sounds (due to the acoustic dampening effect of the pericardial fluid surrounding the heart).
Pulsus Paradoxus : An exaggerated inspiratory drop in systolic blood pressure of > 10 mmHg >10\text{ mmHg} > 10 mmHg during normal spontaneous breathing.
Mechanism (Ventricular Interdependence) : During spontaneous inspiration, negative intrathoracic pressure pulls venous return into the right ventricle. In the rigidly constrained pericardial sac, the expanding right ventricle cannot bulge outward; instead, the interventricular septum bows leftward into the left ventricular cavity . This physically restricts left ventricular filling, causing an abrupt drop in LV stroke volume and systolic pressure during inspiration.
Measurement Technique : Inflate a manual sphygmomanometer cuff above systolic pressure. Deflate slowly at 2 mmHg/second. Note the pressure at which Korotkoff sounds are heard only during expiration . Continue deflating until sounds are heard during both inspiration and expiration . The numerical difference between these two points is the pulsus paradoxus value ( > 10 mmHg >10\text{ mmHg} > 10 mmHg is pathological).
12-Lead ECG Findings :
Sinus Tachycardia : The universal compensatory response to sustained low stroke volume ( C O = H R × S V CO = HR \times SV CO = H R × S V ).
Low QRS Voltage : Total QRS amplitude < 5 mm <5\text{ mm} < 5 mm in all limb leads or < 10 mm <10\text{ mm} < 10 mm in all precordial leads.
Electrical Alternans : Beat-to-beat alternating height, amplitude, and electrical axis of the QRS complex, produced by the physical swinging of the heart back and forth within the large fluid-filled pericardial sac.
Emergent Pericardiocentesis & Nursing Management
Emergency pericardiocentesis is the definitive treatment for cardiac tamponade with hemodynamic instability. Evacuating even 50 to 100 mL of fluid dramatically lowers intrapericardial pressure along the steep portion of the pericardial pressure-volume curve, immediately restoring stroke volume and arterial pressure.
Subxiphoid Needle Insertion Approach :
Position patient at a 30- to 45-degree semi-Fowler's angle (allows fluid to pool dependently in the anterior-inferior pericardium).
Insert an 18-gauge spinal/pericardiocentesis needle between the xiphoid process and the left costal margin, angled 30 to 45 degrees toward the left shoulder under continuous bedside ultrasound guidance.
ECG Lead Monitoring : An alligator clip can be attached from the needle hub to lead V 1 V_1 V 1 of an ECG machine. If the needle contacts the epicardium, the monitor displays dramatic ST-segment elevation (injury pattern) , indicating the needle must be slightly retracted.
Supportive Resuscitation Pearls Prior to Drainage :
Administer an immediate intravenous crystalloid fluid bolus (500 to 1,000 mL normal saline) to expand intravascular volume and temporarily raise right atrial filling pressures above intrapericardial pressure.
AVOID positive pressure mechanical ventilation if possible. Positive intrathoracic pressure reduces venous return to the heart, exacerbates chamber compression, and triggers sudden, fatal cardiovascular collapse.
In-Hospital Cardiac Arrest (IHCA) & ACLS Resuscitation
High-quality cardiopulmonary resuscitation (CPR) and rapid defibrillation are the primary determinants of survival in adult cardiac arrest. Resuscitation follows the American Heart Association (AHA) Advanced Cardiovascular Life Support (ACLS) guidelines.
High-Quality CPR Performance Metrics
CPR Metric AHA Guideline Standard Clinical Rationale & Pitfalls
Compression Depth 2 to 2.4 inches (5 to 6 cm) in adults Maximizes intrathoracic pressure and direct cardiac compression; depths > 2.4 inches >2.4\text{ inches} > 2.4 inches increase thoracic trauma without hemodynamic benefit.
Compression Rate 100 to 120 compressions/minute Optimal rate to generate forward coronary and cerebral perfusion pressures; rates > 120 bpm >120\text{ bpm} > 120 bpm compromise ventricular refill time.
Chest Recoil Complete chest recoil between compressions Allows negative intrathoracic pressure to refill the ventricles and coronary vascular beds; leaning prevents venous return and drops coronary perfusion pressure.
Compression Interruptions Minimize pauses; Chest Compression Fraction (CCF) ≥ 60 % \ge 60\% ≥ 60% , target ≥ 80 % \ge 80\% ≥ 80% Pauses > 10 seconds >10\text{ seconds} > 10 seconds cause immediate loss of coronary perfusion pressure, requiring 10–15 compressions to rebuild perfusion pressure.
Ventilation Strategy Without advanced airway: 30:2 ratio .; With advanced airway: 1 breath every 6 seconds (10 breaths/min) with continuous compressions. Avoid excessive ventilation / hyperventilation ! Hyperventilation increases intrathoracic pressure, decreases venous return to the heart, lowers cardiac output, and reduces cerebral blood flow via hypocapnic vasoconstriction.
End-Tidal C O 2 CO_2 C O 2 ( P E T C O 2 PETCO_2 PETC O 2 ) Continuous quantitative waveform capnography: Target > 10 to 20 mmHg >10\text{ to }20\text{ mmHg} > 10 to 20 mmHg during CPR. Reflects pulmonary blood flow (cardiac output). P E T C O 2 < 10 mmHg PETCO_2 < 10\text{ mmHg} PETC O 2 < 10 mmHg indicates inadequate CPR depth/rate. A sudden, sustained jump to ≥ 35 to 40 mmHg \ge 35\text{ to }40\text{ mmHg} ≥ 35 to 40 mmHg indicates Return of Spontaneous Circulation (ROSC) !
Shockable Rhythms: Ventricular Fibrillation (VF) & Pulseless VT (pVT)
Immediate Unsynchronized Defibrillation : Deliver a high-energy biphasic shock ( 120 to 200 Joules ) as soon as the defibrillator is charged. Immediately resume chest compressions for 2 minutes before performing a rhythm or pulse check.
Vasopressor Therapy : Administer Epinephrine 1 mg IV/IO every 3 to 5 minutes , initiated after the second shockable rhythm check.
Antiarrhythmic Therapy : Administered for shock-refractory VF/pVT:
Amiodarone : First dose 300 mg IV/IO push , followed by a second dose of 150 mg IV/IO push if VF/pVT persists.
Lidocaine (Alternative) : First dose 1.0 to 1.5 mg/kg IV/IO , followed by second doses of 0.5 to 0.75 mg/kg IV/IO (max cumulative dose 3 mg/kg).
Non-Shockable Rhythms: Asystole & Pulseless Electrical Activity (PEA)
In asystole and PEA, defibrillation is ineffective and harmful. Management centers on continuous high-quality CPR, early epinephrine, and identifying reversible underlying causes.
Epinephrine Administration : Administer Epinephrine 1 mg IV/IO as early as possible in the resuscitation sequence, repeated every 3 to 5 minutes.
Reversible Causes: The H's and T's
During cardiac arrest resuscitation, the clinical team must systematically evaluate and treat the reversible causes of pulseless electrical activity and asystole:
Reversible Cause Clinical Assessment & Manifestations Immediate Targeted Nursing & Medical Intervention
Hypovolemia Rapid, narrow-complex tachycardia prior to arrest; flat neck veins; history of hemorrhage, dehydration, or GI bleeding. Rapid IV/IO crystalloid volume challenge (Normal Saline or Lactated Ringer's) or emergency uncrossed O-negative blood products.
Hypoxia Cyanosis, low pulse oximetry before arrest; airway obstruction, mucus plugging, or ventilator disconnection. Verify patent airway, confirm endotracheal tube placement with waveform capnography, ventilate with 100% F i O 2 FiO_2 F i O 2 .
Hydrogen Ion (Acidosis) Known diabetic ketoacidosis, renal failure, or prolonged cardiac arrest with severe metabolic lactic acidosis. Optimize ventilation to blow off C O 2 CO_2 C O 2 ; administer Sodium Bicarbonate (1 mEq/kg IV) for documented severe preexisting metabolic acidosis.
Hypo / Hyperkalemia Hyperkalemia : Peaked T waves, widened QRS, sine wave rhythm, renal failure history.; Hypokalemia : Flattened T waves, U waves, diuretic therapy. Hyperkalemia : IV Calcium Chloride (10%) or Calcium Gluconate (membrane stabilization), IV regular insulin + 50% dextrose, sodium bicarbonate.; Hypokalemia : Cautious IV potassium chloride infusion.
Hypothermia Core body temperature < 30 − 32 ∘ C <30-32^\circ\text{C} < 30 − 3 2 ∘ C ; exposure, drowning, or environmental collapse. Active internal rewarming (warmed humidified oxygen, warmed IV fluids, thoracic lavage, ECMO rewarming); withhold repeated medications until warmed.
Tension Pneumothorax Tracheal deviation, unilateral absent breath sounds, hyperresonance, distended neck veins, severe resistance to manual bag ventilation. Immediate needle decompression (14-gauge catheter at 2nd intercostal space midclavicular line or 4th/5th intercostal space anterior axillary line) followed by chest tube insertion.
Tamponade (Cardiac) Rapid narrow-complex PEA; history of central line placement, cardiac surgery, pacing wire insertion, or pericarditis; distended neck veins. Immediate emergent bedside pericardiocentesis with subxiphoid aspiration under ultrasound guidance.
Toxins Ingestion of beta-blockers, calcium channel blockers, opioids, tricyclic antidepressants, or local anesthetics; bradycardia, prolonged QT. Administer specific antidotes: Naloxone (opioids), High-Dose Insulin + Dextrose (CCBs/beta-blockers), Sodium Bicarbonate (tricyclics), 20% Intralipid (local anesthetics).
Thrombosis (Pulmonary) Sudden PEA arrest; history of DVT, recent immobilization, cancer; right ventricular dilation on bedside echo. Emergent systemic thrombolysis (Alteplase 50-100 mg IV) or surgical/catheter embolectomy; continue CPR for at least 30–60 minutes after thrombolytic administration.
Thrombosis (Coronary) STEMI on pre-arrest ECG; sudden arrest preceded by crushing substernal chest pain and diaphoresis. Mechanical CPR device placement and emergency transport to the cardiac catheterization suite for percutaneous coronary intervention (E-CPR / PCI).